Circulating tumour cells by diagnostic leukapheresis mirror primary tumour heterogeneity in non-small cell lung cancer

Completed

• Conditions: lung cancer; lung carcinoma; non small cell lungcarcinoma; NSCLC; 10038666

• Registration Number: NL-OMON43511
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

Patients with a histologically proven pulmonary malignancy (all disease stages)
Performance status 0-2
Patients using anticoagulants such as fraxodi or acenocoumarol are allowed, unless they have had recent hemorrhagic events
Written informed consent

Exclusion Criteria

Patients with insufficient peripheral venes to undergo leukapheresis
Haemorrhagic diathesis: recent CVA, major bleeding, ulcus duodeni
Cardiac failure, LVEF<40%
No growth factors are allowed

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary outcome is the amount of CTC's and the percentage of patients that we<br /><br>can isolate CTC's in, respective to their disease stage. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Change in CTC count related to response to therapy measured as decrease in size<br /><br>of the tumour, or survival. </p><br>